182 related articles for article (PubMed ID: 12006514)
1. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
[TBL] [Abstract][Full Text] [Related]
2. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
[TBL] [Abstract][Full Text] [Related]
3. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
4. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.
Menon AG; Kuppen PJ; van der Burg SH; Offringa R; Bonnet MC; Harinck BI; Tollenaar RA; Redeker A; Putter H; Moingeon P; Morreau H; Melief CJ; van de Velde CJ
Cancer Gene Ther; 2003 Jul; 10(7):509-17. PubMed ID: 12833131
[TBL] [Abstract][Full Text] [Related]
5. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
Zhu MZ; Marshall J; Cole D; Schlom J; Tsang KY
Clin Cancer Res; 2000 Jan; 6(1):24-33. PubMed ID: 10656428
[TBL] [Abstract][Full Text] [Related]
6. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
7. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
8. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
[TBL] [Abstract][Full Text] [Related]
10. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
11. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
[TBL] [Abstract][Full Text] [Related]
12. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
von Mehren M; Arlen P; Tsang KY; Rogatko A; Meropol N; Cooper HS; Davey M; McLaughlin S; Schlom J; Weiner LM
Clin Cancer Res; 2000 Jun; 6(6):2219-28. PubMed ID: 10873071
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.
Svane IM; Pedersen AE; Johnsen HE; Nielsen D; Kamby C; Gaarsdal E; Nikolajsen K; Buus S; Claesson MH
Cancer Immunol Immunother; 2004 Jul; 53(7):633-41. PubMed ID: 14985857
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
16. Recombinant cancer vaccines based on viral vectors.
Moingeon P
Dev Biol (Basel); 2004; 116():117-22; discussion 133-43. PubMed ID: 15603188
[TBL] [Abstract][Full Text] [Related]
17. Xenovaccinotherapy for colorectal cancer.
Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV
Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887
[TBL] [Abstract][Full Text] [Related]
18. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
[TBL] [Abstract][Full Text] [Related]
19. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
20. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]